The UK is set to become the first country in the world to begin the final phase of the experimental vaccine trial of the coronavirus being developed by Janssen, a subsidiary of Johnson & Johnson.
Scientists will start involving 6,000 people from Monday for a 12-month-long test. Doctor Sol Faust, who is leading the study, said the research will first begin in the UK, but aims to cover 30,000 people in six countries around the world.
Scientists hope that this vaccine will accelerate the body’s immune response to the virus. Faust said Pfizer and his German partner BioNotech had said last week that preliminary data suggest that their vaccine was 90% effective. Faust has described this news as encouraging and welcome for research.